Colorectal cancer screening is an effective tool for catching the disease early when it’s most treatable, yet it is underutilized in patient populations who receive primary care at… read more.
Bayer announced that the FDA has accepted the company’s supplemental new drug application (sNDA) for the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in combination with androgen deprivation… read more.
A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according… read more.
Autolus Therapeutics plc an early-commercial stage biopharmaceutical company developing next-generation programmed T cell therapies, announces the FDA has granted marketing approval for Aucatzyl (obecabtagene autoleucel) for the… read more.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on the results from the LAURA Phase III trial,… read more.
Azurity Pharmaceuticals announced that the FDA has approved Danziten, the first and only nilotinib with no mealtime restrictions indicated for adult patients with newly diagnosed Philadelphia chromosome positive… read more.
Adding treatment with pembrolizumab to standard of care in patients with advanced soft tissue sarcoma of the limb appears to significantly improve disease-free survival, researchers reported on Nov…. read more.
There is a lung cancer screening test that is saving lives – and yet most people who could be getting the test have never heard of it or… read more.
Quitting smoking within six months after a cancer diagnosis adds an average of two years to a patient’s life. With this information in hand, all cancer centers have… read more.
Rigel Pharmaceuticals, Inc. announced it is issuing a Dear Health Care Provider (DHCP) letter related to a new safety signal for Gavreto (pralsetinib) after consultation with the FDA…. read more.
After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy (sacituzumab goviteca-hziy) as a bladder cancer treatment in the U.S. Gilead Sciences announced… read more.
Although breast cancer is the most common non-skin cancer diagnosed in women, finding support during treatment and through survivorship can be incredibly challenging. An analysis of posts from… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
